There are more than five recognized forms of diabetes, but the types most people encounter are Type 1, Type 2, gestational diabetes, LADA (sometimes called Type 1.5), and Type 3c. The American Diabetes Association formally classifies diabetes into four broad categories, while newer research has proposed breaking those categories into five distinct clusters based on how the disease actually behaves in different people. Here’s what sets each type apart and why the distinction matters for treatment.
Type 1 Diabetes
Type 1 diabetes is an autoimmune condition. The immune system attacks and destroys the insulin-producing cells in the pancreas. Once roughly 50% or more of those cells are gone, the body can no longer produce enough insulin to regulate blood sugar, and glucose levels begin to rise. People with Type 1 need to take insulin every day for the rest of their lives because the pancreas eventually produces little to none on its own.
Type 1 is often diagnosed in childhood or adolescence, and younger individuals tend to experience a faster destruction of insulin-producing cells. But it can appear at any age. About 2.1 million people in the United States have diagnosed Type 1 diabetes, including roughly 314,000 children and adolescents under age 20. That makes it a small fraction of the 40.1 million Americans living with diabetes overall.
Type 2 Diabetes
Type 2 accounts for the vast majority of diabetes cases. It develops when the body’s cells gradually stop responding well to insulin, a process called insulin resistance. In the early stages, the pancreas compensates by producing more insulin. Over time, it can’t keep up with demand, and blood sugar stays elevated.
The progression typically looks like this: years of high blood sugar exposure cause cells to become resistant to insulin’s signal. The pancreas works harder, pumping out more insulin to force glucose into cells. Eventually the pancreas wears down, insulin production drops, and blood sugar climbs high enough to cross into prediabetes and then diabetes. Risk factors include excess weight, physical inactivity, and family history, though not everyone with Type 2 fits that profile.
Prediabetes often precedes Type 2 and is diagnosed when fasting blood sugar falls between 100 and 125 mg/dL or A1C is between 5.7% and 6.4%. Full diabetes is diagnosed at a fasting blood sugar of 126 mg/dL or higher, or an A1C of 6.5% or above.
Gestational Diabetes
Gestational diabetes develops during pregnancy, typically diagnosed between 24 and 28 weeks. The hormonal changes of pregnancy can make cells more resistant to insulin, and some women’s bodies can’t produce enough extra insulin to compensate. If you have risk factors like obesity, a family history of diabetes, or a previous pregnancy with gestational diabetes, your provider may screen you earlier.
Screening involves drinking a glucose solution and then having blood drawn at timed intervals. On a one-hour screening test, a blood sugar of 190 mg/dL or higher points to gestational diabetes. If results are borderline, a longer three-hour test checks fasting blood sugar (expected below 95 mg/dL) and levels at one, two, and three hours after the drink. Two or more abnormal readings on that test lead to a diagnosis.
Gestational diabetes usually resolves after delivery, but it raises the risk of developing Type 2 diabetes later in life. Managing blood sugar during pregnancy, through diet, activity, and sometimes insulin, reduces complications for both mother and baby.
LADA (Type 1.5 Diabetes)
Latent autoimmune diabetes in adults, or LADA, is sometimes called Type 1.5 because it shares features of both Type 1 and Type 2. Like Type 1, it involves an autoimmune attack on insulin-producing cells. Like Type 2, it develops in adulthood and progresses slowly enough that it’s frequently misdiagnosed as Type 2 at first.
The clue that someone has LADA rather than Type 2 often comes when oral medications stop working. A person initially manages their blood sugar with lifestyle changes and pills, but over months or years the pancreas loses its ability to produce insulin and they need to start taking it. At that point, providers may order a GAD antibodies test, which looks for immune markers that signal autoimmune destruction of the pancreas. A C-peptide test, which measures how much insulin the pancreas is still producing, can also help distinguish LADA from Type 2.
The ADA formally classifies LADA under the Type 1 umbrella, but many clinicians and patients treat it as its own category because the slower onset changes the treatment timeline significantly.
Type 3c (Pancreatogenic) Diabetes
Type 3c diabetes develops when the pancreas is physically damaged enough to lose its ability to make insulin. This isn’t an autoimmune process or a problem with insulin resistance. It’s structural damage to the organ itself.
The most common causes include chronic pancreatitis, where long-term inflammation scars pancreatic tissue until it can no longer produce enzymes or hormones. Other causes include acute pancreatitis, pancreatic cancer (where tumors damage the organ), cystic fibrosis (where thick mucus scars the pancreas over time), hemochromatosis (where excess iron deposits damage pancreatic tissue), and surgical removal of part or all of the pancreas.
Type 3c is frequently misdiagnosed as Type 2 because the blood sugar patterns can look similar. But the treatment approach differs because the underlying problem is organ damage rather than insulin resistance, and people with Type 3c may also lack the digestive enzymes the pancreas normally produces.
Monogenic Diabetes (MODY)
Monogenic diabetes results from a mutation in a single gene, unlike Type 1 and Type 2 which involve multiple genetic and environmental factors. The most well-known form is MODY, or maturity-onset diabetes of the young. Researchers have identified variants in more than 20 genes that cause monogenic diabetes.
MODY tends to run strongly in families, with multiple generations affected. It’s often diagnosed in adolescence or early adulthood and can be mild enough that some forms don’t require insulin at all, responding instead to specific oral medications. Because it’s uncommon, MODY is frequently misdiagnosed as Type 1 or Type 2. Genetic testing is the only definitive way to identify it, and getting the right diagnosis matters because treatment varies depending on which gene is involved.
The Five-Cluster Model
A landmark study published in The Lancet Diabetes & Endocrinology proposed reclassifying adult-onset diabetes into five distinct clusters based on how the disease actually behaves, rather than sorting it into the traditional categories. Using data on autoimmune markers, insulin production, insulin resistance, body weight, and age at diagnosis, researchers identified five groups:
- Severe autoimmune diabetes (SAID): essentially what we call Type 1, with autoimmune destruction of insulin-producing cells.
- Severe insulin-deficient diabetes (SIDD): people who produce very little insulin but don’t have autoimmune markers. They face high risk of eye disease and nerve damage.
- Severe insulin-resistant diabetes (SIRD): people whose bodies strongly resist insulin’s effects, putting them at elevated risk of kidney disease and fatty liver.
- Mild obesity-related diabetes (MOD): diabetes linked primarily to excess weight, with relatively moderate metabolic disruption.
- Mild age-related diabetes (MARD): the most common cluster, developing later in life with the mildest metabolic changes.
This model hasn’t replaced the standard classification system yet, but it highlights something important: the current categories, especially the broad Type 2 label, lump together people with very different disease patterns and complication risks. Two people both diagnosed with Type 2 may need different treatments and face different long-term outcomes depending on which cluster they actually fall into.